AAV9.SLC6A1 Gene Therapy

Phase 2Gene therapy

EEmily de los Reyes

AAV9.SLC6A1 Gene Therapy is one of 6 biologic programs targeting Neurodevelopment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeurodevelopmentEnrolling by invitation

NeurodevelopmentPhase 2

Enrolling by invitation

Competition

Competitive Landscape

7 competitors in Neurodevelopment

#DrugCompanyPhaseTrials

Medrol

Pfizer

Phase 2

1 2

Rapamune

PPrism Pharmaceuticals

Phase 2

1 3

BPN14770

Shionogi

Phase 2

1 4

AAV9.SLC6A1 Gene Therapy

EEmily de los Reyes

Phase 2

1 5

Recombinant Human Erythropoietin

Amgen

Preclinical

1 6

Vit B12

SSitaram Bhartia Institute of Science and Research

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurodevelopment1 trial

Gene Therapy for SLC6A1 Neurodevelopmental Disorder

Enrolling by invitation·EEmily de los Reyes·Phase 1/2·NCT07173153·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AAV9.SLC6A1 Gene Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AAV9.SLC6A1 Gene Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AAV9.SLC6A1 Gene Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emily de los Reyes company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 2[1]
Company: EEmily de los Reyes

AAV9.SLC6A1 Gene Therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neurodevelopment1 trial

References

Drug Info

Quick Facts

Related News